Wondering how to use Cellectis in a sentence? Below are 7 example sentences from authentic English texts. .
Cellectis in a sentence
Using Cellectis
- In the example corpus, cellectis often appears in combinations such as: of cellectis, cellectis has, cellectis nasdaq.
Context around Cellectis
- Average sentence length in these examples: 17.3 words
- Position in the sentence: 4 start, 2 middle, 1 end
- Sentence types: 7 statements, 0 questions, 0 exclamations
Corpus analysis for Cellectis
- In this selection, "cellectis" usually appears near the start of the sentence. The average example has 17.3 words, and this corpus slice is mostly made up of statements.
- Around the word, marketbeat, earnings and holds stand out and add context to how "cellectis" is used.
- Recognizable usage signals include cellectis holds the and cellectis is not. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "cellectis" sits close to words such as aab, aamer and aave, which helps place it inside the broader word index.
Example types with cellectis
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Four analysts have provided estimates for Cellectis’ earnings. (8 words)
Cellectis is not currently near a potential buying area. (9 words)
Cellectis holds the No. 219 rank among its peers in the Medical-Biomed/Biotech industry group. (16 words)
Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday, November 16th. (33 words)
Bpifrance SA acquired a new position in shares of Cellectis in the first quarter valued at approximately $4,221,000. (20 words)
According to MarketBeat, Cellectis has a consensus rating of Moderate Buy and a consensus price target of $10. (18 words)
Example sentences (7)
According to MarketBeat, Cellectis has a consensus rating of Moderate Buy and a consensus price target of $10.
Bpifrance SA acquired a new position in shares of Cellectis in the first quarter valued at approximately $4,221,000.
Four analysts have provided estimates for Cellectis’ earnings.
Nikko Asset Management Americas Inc. lifted its position in Cellectis by 48.9% in the 2nd quarter.
Cellectis holds the No. 219 rank among its peers in the Medical-Biomed/Biotech industry group.
Cellectis is not currently near a potential buying area.
Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday, November 16th.
Common combinations with cellectis
These word pairs occur most frequently in English texts:
- of cellectis 3×
- cellectis has 2×
- cellectis nasdaq 2×